Algorae Pharmaceuticals Advances AI Drug Platform and Oncology Commercial Push

Living Cell Technologies ( (AU:1AI) ) has provided an update.

Algorae Pharmaceuticals reported strong progress for the December 2025 quarter, highlighted by a new distribution agreement with Dr. Reddy’s Laboratories for Capecitabine 500mg tablets that marks a key step toward oncology revenue in Australia and New Zealand and is backed by a new $3 million debt facility with ScotPac to fund inventory and supply opportunities. On the R&D front, the company launched AlgoraeOS v2, a significantly upgraded AI drug discovery platform that has outperformed leading benchmark models and generated more than 500,000 in silico CBD–drug–cell line predictions, with independent validation of the earlier version at the Peter MacCallum Cancer Centre confirming its predictive power and yielding 90 high-priority combination candidates for further development, supported by a cash inflow from the R&D tax incentive and the forthcoming arrival of a seasoned chief operating officer to scale commercial operations.

The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals is an AI-enabled pharmaceutical development company focused on dual-track growth through AI-driven drug discovery and traditional pharmaceutical commercialisation. Listed on the ASX, the company is building a portfolio of oncology and other medicines in Australia and New Zealand while advancing its proprietary AlgoraeOS platform to identify synergistic drug combinations, with a particular focus on cannabidiol (CBD)-based therapies.

YTD Price Performance: 50.0%

Average Trading Volume: 2,430,225

Technical Sentiment Signal: Buy

Current Market Cap: A$35.46M

Find detailed analytics on 1AI stock on TipRanks’ Stock Analysis page.